After two postponements, Harbin Pharmaceutical Group finally announced its reply to the inquiry letter of Shanghai Stock Exchange on 2018 annual report last night
The global orphan drug market is expanding rapidly, reaching 16 trillion yuan in 2024
Time of Update: 2019-04-28
Specifically, the top 10 pharmaceutical companies in the orphan drug market in the future are Xinji, Bristol Myers Squibb, Novartis, Roche, Johnson & Johnson, shire, Aberdeen, Merck, alexion and Pfizer.
There is only one innovative pharmaceutical enterprise listed in the second batch of listing application list of science and Technology Innovation Board
Time of Update: 2019-04-01
[China Pharmaceutical network industry trends] following the release of the first nine companies accepted on March 22, the Shanghai Stock Exchange announced the second batch
Samsung has officially entered the Chinese medical circle. What is the operation
Time of Update: 2019-01-17
[China Pharmaceutical network industry trends] recently, Sansheng pharmaceutical and Samsung bioepis, a global biopharmaceutical giant, reached a cooperation agreement to conduct
After 8 months, Takeda pharmaceutical completed the acquisition of shire
Time of Update: 2019-01-09
After the merger, Takeda pharmaceutical will have a total annual revenue of more than 30 billion US dollars, mainly from core business areas such as cancer, digestion, neuroscience, rare diseases and blood products (PDT).
Dust settled! Takeda pharmaceutical officially announced the completion of the acquisition of shire
Time of Update: 2019-01-09
Takeda pharmaceutical focuses on the research of cancer, digestion, neuroscience and rare diseases, and promises to invest in research and development of blood products (PDT) and vaccines.
Focusing on drug research and development and new therapy, pharmaceutical giants cut staff one after another
Time of Update: 2018-09-27
[China Pharmaceutical network industry trends] in recent years, the wave of layoffs in the pharmaceutical industry has continued to hit
In the face of large-scale
The trend of layoffs in the pharmaceutical industry is approaching the market reshuffle
Time of Update: 2018-09-21
On September 18, Novo Nordisk's website released a plan to change its research and development mode, announcing 400 job cuts in China and Denmark as part of the restructuring of its research and development department.
[quick news] on July 13, 2018, BASF's third largest chemical production base in the world will be located in Guangdong
Time of Update: 2018-07-13
Http://www.ccin.com.cn/ccin/news/2018/07/10/380872.shtml the signing ceremony of the agreement between Tsinghua University and Beisheng University was held recently.
Jiaying pharmaceutical has released a large amount of "skid" hot money
Time of Update: 2018-05-30
After hours data shows that the first-line hot money Huatai Securities Shenzhen Yitian road Rongchao business center appears to buy a seat.
The sales volume of drug price negotiation varieties soared, with the highest growth rate exceeding 3000%! Auxiliary drugs out of the game, the whole line down! The shuffle of state led pharmaceutical enterprises began
Time of Update: 2018-04-17
Source: on the one hand, on April 17, 2018, more advantageous therapeutic varieties and high price therapeutic drugs for major diseases were gradually included in the medical
Analysis of new drugs under research in 2016
Time of Update: 2016-07-14
Source: pharmaceutical economic news 2016-07-14 with the global pharmaceutical enterprises' attention to the research and development of new drugs and the further clarification
New GMP certification boosts the wave of M & A in pharmaceutical industry
Time of Update: 2016-04-05
Source: China Securities Journal 2016-04-05 due to policy factors such as control of drug fees, the growth of pharmaceutical stocks in previous years was relatively behind
FDA Approves uptravi, and actelion's PAH camp will take another big step
Time of Update: 2015-12-23
Source: China Council for the promotion of drugs 2015-12-23 actelion has been committed to filling this gap since the sales volume of its elderly pulse hypertension (PAH) drug traceer continued to decline.
Shire buys baxalta again to become a special drug dealer for rare diseases
Time of Update: 2015-11-26
Three weeks after announcing a $5.9 billion acquisition of dyax, a US manufacturer of rare disease drugs, shire began preparing to acquire baxalta.
Top 10 per capita output of pharmaceutical enterprises in 2014
Time of Update: 2015-07-27
In 2014, the number of employees of three large pharmaceutical companies also changed significantly.